Qiagen (QGEN) announced the U.S. launch of its therascreen FGFR RGQ RT-PCR Kit as a companion diagnostic to help guide the use of the newly approved FGFR kinase inhibitor, BALVERSA, developed by Janssen Biotech (JNJ). The test will aid in identifying patients with urothelial cancer whose tumors have certain alterations in the fibroblast growth factor receptor 3 gene. The U.S. Food and Drug Administration co-approved the new test with BALVERSA, as announced by Janssen.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.